VIR-7831 constitute a novel class of antibody therapies designed to inhibit the SARS-CoV-2 virus . Originally , sotrovimab, developed by the companies, demonstrated substantial efficacy against strains https://mattiezzqj652091.pointblog.net/sotrovimab-vir-7831-a-deep-exploration-into-the-protein-intervention-94130738